ICI cancer immunotherapy has revolutionized cancer treatment,8 with FDA approval of eight monoclonal antibodies to date blocking the PD-1, PD-L1, or CTLA-4 ICs with many more under investigation. The gene discussed is CTLA4; the disease is cancer.